Navigation Links
Video: EmFinders EmSeeQ(TM) Now Available to Locate Wandering Individuals in Emergency Situations Nationwide
Date:10/14/2009

of Liberty Media Corporation attributed to the Liberty Capital group (Nasdaq: LCAPA), which owns a broad range of electronic retailing, media, communications and entertainment businesses. For more information, visit www.emfinders.com or www.libertymedia.com.

SOURCE EmFinders(TM)


'/>"/>
SOURCE EmFinders(TM)
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ... Phase 3 registration clinical trial for KRX-0401 ... relapsed / refractory multiple myeloma patients. ,, ... Study to Assess the Efficacy and Safety ... Bortezomib (Velcade®) and Dexamethasone in Multiple Myeloma ...
(Date:12/16/2009)... , - MIVI-TRUST ... Total of Over,640 patients Ahead of Schedule ... (Euronext Brussels: THR), a biopharmaceutical company,focused on ... for eye,disease, vascular disease and cancer, announces ... the second Phase III trial evaluating microplasmin ...
(Date:12/15/2009)... Immucor, Inc. (Nasdaq: BLUD ), a global leader ... industry, today announced that it will release its fiscal ... after the market close. The Company will host a ... a.m. (Eastern Time) to discuss the results. ... call by dialing 1-888-324-9321 (Passcode: BLUD). Investors can also ...
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 2Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 3Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 4Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 5Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 7ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 2ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 3ThromboGenics Completes Patient Enrolment of Second Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease 4RES Q Labor Resource Management Scores the Highest Among Staff Nurse Scheduling System Solutions Analyzed in the 2009 KLAS Mid term Performance Review 51064 1RES Q Labor Resource Management Scores the Highest Among Staff Nurse Scheduling System Solutions Analyzed in the 2009 KLAS Mid term Performance Review 51064 2Versus Technology Inc Announces Sale of Real Time Location System to the St Louis VA Medical Center 51059 1Versus Technology Inc Announces Sale of Real Time Location System to the St Louis VA Medical Center 51059 2Versus Technology Inc Announces Sale of Real Time Location System to the St Louis VA Medical Center 51059 3Actor Chris Noth to Share Story of Loss in National Life Insurance Awareness Month 51054 1Actor Chris Noth to Share Story of Loss in National Life Insurance Awareness Month 51054 2Actor Chris Noth to Share Story of Loss in National Life Insurance Awareness Month 51054 3
... Shire plc (LSE: SHP, Nasdaq: SHPGY ), the ... that coadministration of the ADHD medication VYVANSE(R) (lisdexamfetamine dimesylate) CII ... (20 mg X 2), did not alter the median time ... to be reached in the subjects evaluated. In the ...
... trials begin enrollment in May 2009; Reinforces Lilly,s commitment ... 21 Eli Lilly and Company (NYSE: ... this month in two separate but identical Phase III ... an anti-amyloid beta monoclonal antibody being investigated as a ...
Other Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 2Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 3Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 4Lilly Advances Second Alzheimer's Disease Treatment Candidate Into Late-Stage Testing by Launching Two Global Trials 5
(Date:12/16/2009)... , , TUESDAY, Dec. 15 (HealthDay News) -- If that ... on your life that you just can,t wait to have ... you might want to wait at least six months before ... be even better. , The study found that when ... chances of the baby dying, being born prematurely, having birth ...
(Date:12/16/2009)... has received a further 1.6 million Euro in capital funding ... System in order to meet the rapidly growing demand for this ... Unisense A/S that continue to own each about 50% of the ... ... -- Unisense FertiliTech A/S has received a further 1.6 million Euro ...
(Date:12/16/2009)... Request A Test, Ltd. is proud to announce being presented with ... Weatherhead 100 showcases the fastest growing companies in Northeast Ohio and ... to succeed. , ... (PRWEB) December ... being presented with the Weatherhead 100 Upstart Award on December 3, ...
(Date:12/16/2009)... & Ennis, P.A. will continue to offer free nationwide confidential ... serious Paxil side effects such as: Birth Defects, Attempted Suicide, ... can call toll free at 1-800-856-6405 or go to the ... online case evaluation form. , ... ...
(Date:12/15/2009)... developed a new electrophoretic method for detecting MIRCERA ... The technique, using SARCOSYL-PAGE, has specifically enhanced sensitivity ... characteristics of SDS-PAGE for detecting other EPOs. ... from the World Anti-Doping Agency (WADA), appear in ... Analysis published by Wiley-Blackwell. , MIRCERA (methoxy ...
Breaking Medicine News(10 mins):Health News:For Babies' Sake, Pregnancy Spacing Matters 2Health News:For Babies' Sake, Pregnancy Spacing Matters 3Health News:Increased Capital Funding for Unisense FertiliTech A/S Will Help Meet Demand for New Assisted Reproduction Device 2Health News:Request A Test Receives Weatherhead 100 Upstart Award 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free Legal Consultations For Users of Paxil 3Health News:Researchers discover novel method for detecting MIRCERA 2
... EL SEGUNDO, Calif., Dec. 27 Computer ... that it has signed an extension to,a ... with Sun Microsystems Inc., Under the ... all,applications development and support services for Sun,s ...
... FDA -, MENLO PARK, Calif., Dec. 27 ... drug-eluting stent (DES),systems, today announced that it has submitted ... Mark approval of its Custom NX DES,System., XTENT,s ... the,drug formulation submission from Biosensors International Group. XTENT,plans to ...
... Dec. 26 Whether it,s living and dying with,every ... the nachos and pizza,that make up the game watching ... of heartburn. Prilosec OTC, the number one selling OTC,heartburn ... opportunity to,win tickets to Super Bowl forty-two in Glendale, ...
... they don,t address benefits of drug therapy , , WEDNESDAY, ... out abnormal heart tissue reduces the number of shocks ... attacks, a new trial showed. , While those shocks ... abnormal rhythms, they are desirable to avoid not only ...
... MELVILLE, N.Y., Dec. 26 Gentiva Health,Services, Inc. (Nasdaq: ... health and related services, announced today that it is,scheduled ... Tuesday, January 8,2008 at the 26th Annual JPMorgan Healthcare ... available to the public via a live audio web ...
... NEW YORK, Dec. 26 Immtech Pharmaceuticals,Inc. (Amex: ... working with clinical,investigators at the South African site ... (DB289), an investigational therapy. In preliminary,findings from the ... following treatment with pafuramidine. The Company has discussed,the ...
Other Medicine News:Health News:CSC Signs Extension to Managed Applications Services Agreement With Sun Microsystems 2Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 2Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 3Health News:Heart Procedure Reduces Need for Defibrillator Shocks 2Health News:Heart Procedure Reduces Need for Defibrillator Shocks 3Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 2Health News:Gentiva(R) Health Services to Present January 8 at JPMorgan Healthcare Conference in San Francisco 3Health News:Immtech Announces Pafuramidine (DB289) Program on Clinical Hold 2Health News:Immtech Announces Pafuramidine (DB289) Program on Clinical Hold 3
... is a sensitive, simple to ... the detection of all major ... can distinguish between P. ... vivax . In addition, the ...
... is a two site sandwich ... the detection of P. falciparum ... HRP-2) and P. vivax specific ... be used for specific detection ...
The Cellabs Rapimal (P.f.) is a rapid and sensitive in vitro immunochromatography assay system for the detection of HRP-2 antigen produced by P. falciparum at the merozoite (red blood cell) stage o...
An immunochromatographic rapid test for the detection of Plasmodium falciparum in whole blood....
Medicine Products: